Thrombolytic treatment significantly reduces mortality among patients treated with SK compared to controls, receiving conventional treatments: 10.7% SK vs 13% controls, for an 18% reduction (p=.0002, relative risk (RR) 0.81, 95%CI: 0.72-0.90).